All In Biotech

Drug Trial Radar · NCT03479307

A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

A Multi-Center, Double-Masked, Randomized, Vehicle- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Bilastine Ophthalmic Solution 0.6% Compared to Vehicle and Zaditen (Ketotifen Ophthalmic Solution 0.025%) for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model

Last checked: Nov 19, 2026Latest source record: Mar 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

228

Actual

Start

Apr 7, 2018

Primary completion

Aug 9, 2018

Study completion Aug 10, 2018

Sponsor

Lead sponsor
Faes Farma, S.A.Industry
Sponsor type
Industry
Collaborators
ORA, Inc.
First posted
Mar 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

  • Bilastine Ophthalmic Solution 0.6%Drug

    1 drop in each eye at 2 separate times during an 8 day period.

  • Ketotifen Ophthalmic Solution 0.025% (Zaditen)Drug

    1 drop in each eye at 2 separate times during an 8 day period.

  • Vehicle of Bilastine Ophthalmic SolutionDrug

    1 drop in each eye at 2 separate times during an 8 day period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular ItchingTime frame: The outcome measure was assessed at Visit 4b (Day 1: 16h post-treatment) and Visit 5 (Day 8 ±3, 15 minutes post-treatment).

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Cornea Consultants of AZ

    Phoenix, Arizona

  • East West Eye Institute

    Torrance, California

  • Andover Eye Associates

    Andover, Massachusetts

  • Apex Eye

    Mason, Ohio

  • Philadelphia Eye Associates

    Philadelphia, Pennsylvania

  • Total Eye Care, P.A.

    Memphis, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.